https://scholars.lib.ntu.edu.tw/handle/123456789/570859
Title: | Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients | Authors: | Lee M.-H. Huang C.-F Lai H.-C Lin C.-Y Dai C.-Y CHUN-JEN LIU Wang J.-H Huang J.-F Su W.-P HUNG-CHIH YANG Kee K.-M Yeh M.-L Chuang P.-H SHIH-JER HSU Huang C.-I JIA-HORNG KAO CHIEH-CHANG CHEN Chen S.-H Jeng W.-J Yang H.-I Yuan Y Lu S.-N Sheen I.-S CHEN-HUA LIU Peng C.-Y Yu M.-L Chuang W.-L Chen C.-J. |
Issue Date: | 2017 | Publisher: | Nature Publishing Group | Journal Volume: | 7 | Journal Issue: | 1 | Source: | Scientific Reports | Abstract: | This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored. ? 2017 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020937931&doi=10.1038%2fs41598-017-02313-y&partnerID=40&md5=485b763b1209b6646ee4eccec2d46cfa https://scholars.lib.ntu.edu.tw/handle/123456789/570859 |
ISSN: | 2045-2322 | DOI: | 10.1038/s41598-017-02313-y | SDG/Keyword: | antivirus agent; biological marker; adult; aged; blood; chronic hepatitis C; complication; female; genetics; genotype; Hepacivirus; human; incidence; liver cell carcinoma; liver cirrhosis; liver tumor; male; middle aged; proportional hazards model; risk assessment; risk factor; treatment outcome; virology; Adult; Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Treatment Outcome |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.